688331 RemeGen Co., Ltd.
- 45.68
- -0.52-1.13%
RemeGen Co., Ltd. News
Rongchang Biotech (688331): Continued high revenue growth, looking forward to overseas progress
Rongchang Biology (688331): Commercialization is progressing steadily and clinical trials at home and abroad are progressing smoothly
Rongchang Biology (688331): R&D continues to progress smoothly in the research pipeline
Changes in Hong Kong stocks 丨 Rongchang Biotech rose more than 6%, institutions are bullish on its target price to HK$56
BOC International: Maintaining Rongchang Biotech's (09995.HK) “Buy” Rating Target Price of HK$56
Rongchang Biotech (9995.HK): Strong sales of 1Q24 products and loss reduction, important catalysts will soon be concentrated on implementation to maintain purchases
Rongchang Biology (688331): Commercialization promotion, good clinical pipeline progressing in an orderly manner
Rongchang Biotech (9995.HK): Overseas pipeline promotion and authorization of a new star that is deeply involved in self-avoidance+cancer BIOPHARMA can be anticipated
Rongchang Biotech (9995.HK): 1Q24 net loss is in line with expectations; the company maintains 2024 revenue guidance
CCB International: Maintaining Rongchang Biotech's (09995.HK) “Outperform the Market” rating and raising the target price to HK$34
Guoxin Securities released a research report on April 8 stating that it gave Rongchang Biotech (688331.SH) an increase in its holdings. The main reasons for the rating include: 1) commercialization of core products is progressing well; 2) clinical promoti
Rongchang Biotech (9995.HK): Strong revenue growth, clinical progress continues to be steady
Rongchang Biotech (688331): Sales of core products continue to grow, clinical development progresses in an orderly manner
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ramsay Health Care (OtherRMSYF), Glass House Brands (OtherGLASF) and RemeGen Co. Ltd. Class H (HK:9995)
Rongchang Biotech (688331): Strong commercialization of main products, growing innovative drug echelons
REMEGEN(9995.HK):AWAITING THE FRUITION OF OVERSEAS BD COLLABORATIONS
REMEGEN CO LTD(9995.HK):SOFT COMMERCIALISATION IN 2023;GUIDANCE OF AT LEAST 50% YOY GROWTH IN DRUG SALES IN 2024
REMEGEN(09995.HK):SALES RAMP UP WITH R&D ACHIEVEMENTS
Rongchang Biotech (688331): Core product volume+offshore +fixed growth BIOTECH leader has set sail again
Rongchang Biotech (688331): Sales of core products increased significantly, and the pace of overseas clinical progress accelerated
Analysis
Price Target
No Data
